GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sernova Corp (FRA:PSH) » Definitions » Cyclically Adjusted PS Ratio

Sernova (FRA:PSH) Cyclically Adjusted PS Ratio : (As of Apr. 27, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Sernova Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Sernova Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Sernova's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sernova Cyclically Adjusted PS Ratio Chart

Sernova Annual Data
Trend Oct14 Oct15 Oct16 Oct17 Oct18 Oct19 Oct20 Oct21 Oct22 Oct23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Sernova Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Sernova's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Sernova's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sernova's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sernova's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Sernova's Cyclically Adjusted PS Ratio falls into.



Sernova Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Sernova's Cyclically Adjusted Revenue per Share for the quarter that ended in Jan. 2024 is calculated as:

For example, Sernova's adjusted Revenue per Share data for the three months ended in Jan. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Jan. 2024 (Change)*Current CPI (Jan. 2024)
=0/125.4675*125.4675
=0.000

Current CPI (Jan. 2024) = 125.4675.

Sernova Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201404 0.000 98.920 0.000
201407 0.000 99.315 0.000
201410 0.000 99.473 0.000
201501 0.000 98.209 0.000
201504 0.000 99.710 0.000
201507 0.000 100.579 0.000
201510 0.000 100.500 0.000
201601 0.000 100.184 0.000
201604 0.000 101.370 0.000
201607 0.000 101.844 0.000
201610 0.000 102.002 0.000
201701 0.000 102.318 0.000
201704 0.000 103.029 0.000
201707 0.000 103.029 0.000
201710 0.000 103.424 0.000
201801 0.000 104.056 0.000
201804 0.000 105.320 0.000
201807 0.000 106.110 0.000
201810 0.000 105.952 0.000
201901 0.000 105.557 0.000
201904 0.000 107.453 0.000
201907 0.000 108.243 0.000
201910 0.000 107.927 0.000
202001 0.000 108.085 0.000
202004 0.000 107.216 0.000
202007 0.000 108.401 0.000
202010 0.000 108.638 0.000
202101 0.000 109.192 0.000
202104 0.000 110.851 0.000
202107 0.000 112.431 0.000
202110 0.000 113.695 0.000
202201 0.000 114.801 0.000
202204 0.000 118.357 0.000
202207 0.000 120.964 0.000
202210 0.000 121.517 0.000
202301 0.000 121.596 0.000
202304 0.000 123.571 0.000
202307 0.000 124.914 0.000
202310 0.000 125.310 0.000
202401 0.000 125.468 0.000

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Sernova  (FRA:PSH) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Sernova Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Sernova's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Sernova (FRA:PSH) Business Description

Industry
Traded in Other Exchanges
Address
700 Collip Circle, The Stiller Centre, Suite 114, London, ON, CAN, N6G 4X8
Sernova Corp is a clinical-stage company developing products for the treatment of chronic debilitating diseases. The company is engaged in the research and development of its proprietary Cell Pouch and associated technologies including immune-protected therapeutic cells. The Cell Pouch is a scalable, implantable medical device designed to create a vascularized tissue environment for the transplantation and engraftment of therapeutic cells, which then release proteins and or hormones for the long-term treatment of multiple serious, chronic diseases such as diabetes, hemophilia, and thyroid disease.

Sernova (FRA:PSH) Headlines